home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Software Vault: The Diamond Collection
/
The Diamond Collection (Software Vault)(Digital Impact).ISO
/
cdr16
/
med9505a.zip
/
M9550005.TXT
< prev
next >
Wrap
Text File
|
1995-03-04
|
2KB
|
28 lines
Document 0005
DOCN M9550005
TI Azole resistance in oropharyngeal Candida albicans strains isolated from
patients infected with human immunodeficiency virus.
DT 9505
AU He X; Tiballi RN; Zarins LT; Bradley SF; Sangeorzan JA; Kauffman CA;
Department of Internal Medicine, University of Michigan Medical; School,
Ann Arbor.
SO Antimicrob Agents Chemother. 1994 Oct;38(10):2495-7. Unique Identifier :
AIDSLINE MED/95142605
AB For 212 oropharyngeal isolates of Candida albicans, the fluconazole MICs
for 50 and 90% of strains tested were 0.5 and 16 micrograms/ml,
respectively, and those of itraconazole were 0.05 and 0.2 micrograms/ml,
respectively. Of 16 isolates for which fluconazole MICs were > 64
micrograms/ml, itraconazole MICs for 14 were < or = 0.8 micrograms/ml
and for 2 were > 6.4 micrograms/ml. Most fluconazole-resistant strains
remained susceptible to itraconazole; whether itraconazole will prove
effective for refractory thrush remains to be shown.
DE AIDS-Related Opportunistic Infections/*MICROBIOLOGY Candida
albicans/*DRUG EFFECTS Drug Resistance, Microbial
Fluconazole/*PHARMACOLOGY Human Itraconazole/*PHARMACOLOGY Microbial
Sensitivity Tests Oropharynx/*MICROBIOLOGY Support, Non-U.S. Gov't
JOURNAL ARTICLE
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).